KOLEK, V., I. GRYGÁRKOVÁ, J. CHALUPA, L. KOUBKOVÁ, J. ŠVECOVÁ, Jana SKŘIČKOVÁ, L. OSTŘÍŽKOVÁ and D. SIXTOVÁ. Oral vinorelbine in combination with cisplatin or carboplatin in adjuvant chemotherapy of non-small cell lung cancer: A prospective multicentre study of feasibility, tolerability and 3-year survival. In 13th Central European Lung Cancer Conference. 2012. ISSN 0169-5002. doi:10.1016/j.lungcan.2012.05.063.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Oral vinorelbine in combination with cisplatin or carboplatin in adjuvant chemotherapy of non-small cell lung cancer: A prospective multicentre study of feasibility, tolerability and 3-year survival
Authors KOLEK, V., I. GRYGÁRKOVÁ, J. CHALUPA, L. KOUBKOVÁ, J. ŠVECOVÁ, Jana SKŘIČKOVÁ, L. OSTŘÍŽKOVÁ and D. SIXTOVÁ.
Edition 13th Central European Lung Cancer Conference, 2012.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.392
Organization unit Faculty of Medicine
ISSN 0169-5002
Doi http://dx.doi.org/10.1016/j.lungcan.2012.05.063
Keywords in English lung cancer; erlotinib
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 17. 8. 2012 14:10.
Abstract
Adjuvant cisplatinum-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA of non small-cell lung cancer (NSCLC) after radical resection. Results in stage IB were not conclusive. Vinorelbine is a preferable associated drug in this indication and a randomized study proved the comparable effectiveness and tolerability of vinorelbine given both orally or intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine gives better comfort to patients.
PrintDisplayed: 21. 5. 2022 15:14